The Annals Take our Readership Survey!
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     


Published Online, 27 February 2004, www.theannals.com, DOI 10.1345/aph.1D297.
 The Annals of Pharmacotherapy: Vol. 38, No. 4, pp. 686-693. DOI 10.1345/aph.1D297
© 2004 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bell, E. A
Right arrow Articles by Wall, G. C
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bell, E. A
Right arrow Articles by Wall, G. C

PEDIATRICS

Pediatric Constipation Therapy Using Guidelines and Polyethylene Glycol 3350

Edward A Bell, PharmD BCPS

Associate Professor of Pharmacy Practice, College of Pharmacy and Health Sciences, Drake University, Des Moines, IA

Geoffrey C Wall, PharmD BCPS

Assistant Professor of Pharmacy Practice, College of Pharmacy and Health Sciences, Drake University

Reprints: Edward A Bell PharmD BCPS, College of Pharmacy and Health Sciences, Drake University, 2507 University Ave., Des Moines, IA 50311-4505, fax 515/271-1867, ed.bell{at}drake.edu

OBJECTIVE: To review current guidelines on the treatment of functional constipation in pediatric patients, with an emphasis on the role of polyethylene glycol 3350 (PEG 3350).

DATA SOURCES: Primary medical literature published in English was identified by MEDLINE search (1980–May 2003).

STUDY SELECTION AND DATA EXTRACTION: Recently published treatment guidelines relating to pediatric functional constipation and its pharmacotherapy are assessed and compared. Published trials evaluating PEG 3350 in pediatric subjects are discussed and their results applied to the clinical role and use of this new agent.

DATA SYNTHESIS: Constipation is a common disorder among children. A number of factors may play a role. A variety of medications are commonly used for this disorder, although few treatments have undergone evaluation by controlled clinical trials. Consensus guidelines recommend either osmotic laxatives, mineral oil, or their combination for maintenance treatment in concert with patient and parental education and behavioral training. PEG 3350 solution (MiraLax) has been shown in recent clinical studies to be an effective maintenance treatment for pediatric constipation.

CONCLUSIONS: PEG 3350 is an effective and well-tolerated treatment choice for pediatric constipation, especially as an adjunct to education and behavioral training. PEG 3350 is an option for children with constipation who have failed or are intolerant of other pharmacotherapies.

Key Words: children, constipation, polyethylene glycol 3350

Published Online, February 27, 2004. www.theannals.com, DOI 10.1345/aph.1D297

THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
ACPE UNIVERSAL PROGRAM NUMBER: 407-000-04-016-H01


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
R. Webster, E. Didier, P. Harris, N. Siegel, J. Stadler, L. Tilbury, and D. Smith
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
Drug Metab. Dispos., January 1, 2007; 35(1): 9 - 16.
[Abstract] [Full Text] [PDF]

Home page
 CLIN PEDIATRHome page
L. Butani
Letter to the Editor
Clinical Pediatrics, January 1, 2005; 44(1): 93 - 93.
[PDF]


homecopy help contact us subscription past issues search current issue
Copyright © 2004 by Harvey Whitney Books Company.